Evelo Biosciences, Inc.: Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights
-Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting-
-Strengthened leadership team with appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to Board of Directors-
-Announced strategic collaboration with Abdul Latif Jameel Health to develop and commercialize EDP1815 in select developing markets-
-Multiple clinical data readouts expected over next 18 months-
-Management to host conference call at 8:30 a.m. ET-
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the first quarter 2021.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights
Evelo Biosciences, Inc.April 29, 2021 GMT
–Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting– –Strengthened leadership team with appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to Board of Directors– –Announced strategic collaboration with Abdul Latif Jameel Health to develop and commercialize EDP1815 in select developing markets– –Multiple clinical data readouts expected over next 18 months– –Management to host conference call at 8:30 a.m. ET–
LEO Pharma
LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021
Monday, April 26, 2021 1:00PM IST (7:30AM GMT)
Ballerup, Denmark & Madison, N.J., United States:
Interim analysis at 56 weeks from ECZTEND, an open-label extension trial, demonstrates sustainable and durable efficacy of tralokinumab in adult patients
1
Patients enrolled in ECZTRA 1 and 2 parent trials who continued into ECZTEND have now been treated with tralokinumab for two years
1
1
LEO Pharma A/S, a global leader in medical dermatology, today announced results on the long-term safety and efficacy profile of tralokinumab in adult patients with moderate-to-severe atopic dermatitis. Results were shared as an oral presentation during the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 2021.
Multidisciplinary Approach Touted for Atopic Dermatitis medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Hits: 60
If authorized, Adtralza
® (tralokinumab) will be the first approved biologic that specifically targets the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms
1,2
The CHMP opinion is primarily supported by data from ECZTRA 1, 2, and 3 trials included in the Marketing Authorization Application
BALLERUP, Denmark I April 23, 2021 I LEO Pharma A/S, a global leader in medical dermatology, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization of Adtralza
® (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.